Evidence map›Paper›PMID 23103679›Full record

ReviewBone marrow transplantation2013

Trimming the fat: obesity and hematopoietic cell transplantation.

B M Weiss, D T Vogl, N A Berger, E A Stadtmauer, H M Lazarus

Abstract readReview
PubMed Publisher
In one paragraph

Review in Bone marrow transplantation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Assessing the impact of nutritional status at allogeneic stem cell transplantation on clinical outcomes.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Obesity and cancer pathogenesis.Annals of the New York Academy of Sciences · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

B M WeissHematologic Malignancies and Bone Marrow Transplant Program, Abramson Cancer Center, University of Pennsylvania, Perelman Center for Advanced Medicine-2 West, Philadelphia, PA 19104, USA. brendan.weiss@uphs.upenn.edu
D T Vogl
N A Berger
E A Stadtmauer
H M Lazarus
University of Pennsylvania · USCase Western Reserve University · USUniversity Hospitals Case Medical Center · US

Funding

Transdisciplinary Research on Energetics and CancerU54CA116867 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI BERGER, NATHAN A. · 2005 to 2010
$11.3M
Aging-Cancer Research Program Development at CWRU CCCP20CA103736 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI BERGER, NATHAN A. · 2003 to 2007
$3.8M
NCI NIH HHS P20 CA103736NCI NIH HHS U54 CA116867PHS HHS P20 103736
6 · The paper itself

Abstract

Obesity, increasing worldwide, is common in patients undergoing hematopoietic cell transplantation (HCT). This complex physiological state may alter the outcome of cancer therapies by many mechanisms including direct effects on pathogenesis, host responses to disease and altered pharmacology of chemotherapy. Obesity has been associated with multiple adverse health outcomes. Reports of obese patients undergoing HCT are challenging to interpret because of the heterogeneity of obesity definitions, underlying diseases, graft sources and chemotherapy regimens employed. Compared with normal-weight patients, it appears that obese patients undergoing allogeneic HCT have a higher risk of non-relapse mortality and inferior survival whereas those receiving autologous HCT appear to have equivalent outcomes. These findings are also difficult to interpret because there is no consistent standard for calculating chemotherapy dose in this group and future studies on specific regimens in this population are urgently needed. Patients who have undergone bariatric surgery may be at risk for unexpected events because of impaired nutritional state and altered pharmacokinetics of oral drugs. We recommend that future studies utilize more consistent and biologically relevant definitions of obesity and that the pharmacokinetics and pharmacodynamics of specific conditioning regimens be studied. Until more evidence is available, a rationale is presented for dosing based on adjusted body weight. Moreover, recommendations are provided to guide future research efforts based on more definitive measurements of body fat and its distribution available through modern quantitative imaging techniques using dual energy X-ray absorptiometry or magnetic resonance imaging scanning.

Indexed as

AnimalsDisease-Free SurvivalHematopoietic Stem Cell TransplantationHumansObesityTransplantation ConditioningTransplantation, HomologousTreatment Outcome

Identifiers

PMID23103679
OpenAlexW1995372018

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.